Oxford Nanopore Technologies reported first-half revenue of £116.5 million, growing 10% but below expectations due to declines in China and the Middle East. Despite the setback, the company maintains its full-year revenue growth forecast of 21% to 25% at constant currency, expecting a stronger second half supported by applied markets and new business. Cash reserves decreased to £234.5 million by June, and the company aims to reach adjusted earnings breakeven in 2027. Interim results are due on August 19.
Noble Capital Markets has initiated equity research coverage on VivoPower PLC, assigning an Outperform rating and setting a price target of $10. VivoPower is a B Corp-certified global developer of powered land and data center infrastructure for AI ap...
The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a 10.5% CAGR from 2026 to 2036, driven by rising cancer incidence and new immunotherapy launches. Key emerging therapies from companies like Johnson & Johnson, BioNTech,...
Alamar Biosciences has partnered with top U.S. research universities to start a nationwide proteomics project using its NULISAseq™ Neuro 220 panel. The study will analyze about 21,000 plasma samples from 10,000 Alzheimer's and related dementia partic...
Alamar Biosciences has partnered with leading U.S. universities to launch a nationwide proteomics study analyzing around 21,000 plasma samples from 10,000 Alzheimer's and related dementia patients. Using its NULISAseq™ Neuro 220 test kit, the project...
VINCI SA announced it repurchased a total of 400,000 treasury shares from July 6 to July 10, 2026, under authorization from its April 2026 General Meeting. The shares were bought at an average weighted price of approximately €120.99 per share across ...
